Navigation Links
EndoSphere Inc. Announces Pivotal Financing Led by Broadline Capital
Date:6/1/2011

COLUMBUS, Ohio, June 1, 2011 /PRNewswire/ -- EndoSphere Inc., a medical technology company developing a platform of endoscopically implantable devices for the treatment of metabolic diseases, including obesity and type 2 diabetes, announced today the completion of a highly oversubscribed Series A Preferred Financing round led by Broadline Capital, a global private equity investment firm.  EndoSphere Inc., which holds 23 U.S. and international issued and pending patents, will use the funding to expand its intellectual property assets and to complete additional clinical product testing.

"EndoSphere is extremely fortunate to align itself with Broadline Capital, which offers a rare blend of global financial expertise and pragmatic operating experience," said James McKinley, EndoSphere CEO.

Broadline Capital was formed in 2005 by Christopher Thorne, an early pioneer in China's private equity industry and former management consultant at McKinsey & Company.  Thorne previously founded and developed a software technology company that created efficiency gains for manufacturers, distributors and retailers in the trillion-dollar food and beverage, consumer packaged goods and retail supply chains.  The resulting company sold to institutional investors at a nine-figure enterprise valuation in 2007.

"An investment in EndoSphere presented us with a unique opportunity to invest in, and support, an exciting portfolio of intellectual property assets and a highly experienced management team," said Thorne. "EndoSphere's technology brings an innovative approach to treating obesity, which has become one of the largest health problems worldwide."

The company is planning a multi-center clinical trial while continuing its research and development of innovative and profitable applications.  

"With the support of this financing, EndoSphere is poised to fulfill the potential of the technology and the expectations of the investors," commented McKinley.

Broadline Capital's co-investing partners in EndoSphere's Series A Preferred Financing include investment firm Glengary LLC, Physician Investment Group LLC, and several of the nation's largest angel investment funds including Ohio TechAngel Funds II and III, North Coast Angel Fund II, and QCA First Fund III.

About EndoSphere Inc.

EndoSphere Inc. is a medical technology company that develops and commercializes devices including the SatiSphere™ duodenal insert, which treats one of the most critical healthcare issues in the world today: obesity and its co-morbidities. EndoSphere is a Delaware corporation founded in 2006 in Redwood City, California and is now headquartered in Columbus, Ohio.

About Broadline Capital

Broadline Capital is a global private equity investment firm with offices in the U.S. and China.  The firm was founded in 2005 by Christopher Thorne to provide capital, expertise and management support to promising companies within highly charged markets. Leading some of the most creative deals in its market categories, Broadline Capital received the private equity industry's "Deal of the Year" award in Asia, named by Private Equity International for a 2007 China investment.  For more information about Broadline Capital, please visit www.BroadlineCapital.com.

Contact:
Bryan Kozlowski, Financial Controller
EndoSphere Inc.
Phone: 614.245.0338


'/>"/>
SOURCE EndoSphere Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
Breaking Medicine News(10 mins):